CN106349138A - 用于制备前列腺素酰胺的新的方法 - Google Patents

用于制备前列腺素酰胺的新的方法 Download PDF

Info

Publication number
CN106349138A
CN106349138A CN201610630836.9A CN201610630836A CN106349138A CN 106349138 A CN106349138 A CN 106349138A CN 201610630836 A CN201610630836 A CN 201610630836A CN 106349138 A CN106349138 A CN 106349138A
Authority
CN
China
Prior art keywords
formula
group
bimatoprost
ether
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610630836.9A
Other languages
English (en)
Chinese (zh)
Inventor
G.哈瓦西
T.基斯
I.霍托巴吉
Z.卡多斯
I.拉兹洛菲
Z.比肖夫
A.伯蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU1100291A external-priority patent/HU230703B1/hu
Priority claimed from HU1100292A external-priority patent/HU231134B1/hu
Application filed by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt filed Critical Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Publication of CN106349138A publication Critical patent/CN106349138A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
CN201610630836.9A 2011-06-02 2012-05-25 用于制备前列腺素酰胺的新的方法 Pending CN106349138A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HUP1100291 2011-06-02
HUP1100292 2011-06-02
HU1100291A HU230703B1 (hu) 2011-06-02 2011-06-02 Új eljárás prosztaglandin amidok előállítására
HU1100292A HU231134B1 (hu) 2011-06-02 2011-06-02 Eljárás a bimatoprost kémiailag stabil új kristályformájának előállítására
CN201280027006.7A CN103649047B (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280027006.7A Division CN103649047B (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的方法

Publications (1)

Publication Number Publication Date
CN106349138A true CN106349138A (zh) 2017-01-25

Family

ID=89990312

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201610630836.9A Pending CN106349138A (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的新的方法
CN201610657048.9A Active CN106278982B (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的新的方法
CN201280027006.7A Active CN103649047B (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的方法
CN201610603047.6A Pending CN106316910A (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的新的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201610657048.9A Active CN106278982B (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的新的方法
CN201280027006.7A Active CN103649047B (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的方法
CN201610603047.6A Pending CN106316910A (zh) 2011-06-02 2012-05-25 用于制备前列腺素酰胺的新的方法

Country Status (17)

Country Link
US (3) US9238621B2 (enExample)
EP (1) EP2723714B1 (enExample)
JP (3) JP6212485B2 (enExample)
KR (3) KR102135550B1 (enExample)
CN (4) CN106349138A (enExample)
BR (3) BR112013030973B1 (enExample)
CA (3) CA3094762C (enExample)
ES (1) ES2636756T3 (enExample)
HU (1) HUE033642T2 (enExample)
IL (1) IL229647A (enExample)
MX (1) MX341839B (enExample)
PL (1) PL2723714T3 (enExample)
PT (1) PT2723714T (enExample)
RU (1) RU2618223C2 (enExample)
TW (3) TWI653223B (enExample)
WO (1) WO2012164324A1 (enExample)
ZA (1) ZA201309357B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231203B1 (hu) 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
HU231214B1 (hu) * 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
WO2015199729A1 (en) * 2014-06-27 2015-12-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
HU231185B1 (hu) * 2017-07-11 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás Misoprostol előállítására és tisztítására
CN113548993B (zh) * 2021-09-01 2022-05-27 河北化工医药职业技术学院 一种卡前列素的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533372A (zh) * 2001-07-17 2004-09-29 �������Ŷ���Լ��������˾ 制备拉坦前列腺素的方法和中间体
CN1774417A (zh) * 2001-05-31 2006-05-17 梵泰克实验室有限公司 17－苯基－18,19,20－去三甲－前列腺素F2α及其衍生物的制备方法
US20090163596A1 (en) * 2006-08-29 2009-06-25 Arie Gutman Bimatoprost crystalline form I

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954741A (en) * 1972-06-07 1976-05-04 Pfizer Inc. N-substituted prostaglandin carboxamides
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
HU171155B (hu) * 1973-04-30 1977-11-28 Pfizer Sposob poluchenija oksa-prostaglandinov
HU175889B (en) 1976-04-08 1980-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing lactol-alcohol derivatives
HU175217B (hu) * 1977-08-03 1980-06-28 Chinoin Gyogyszer Es Vegyeszet Novyj sposob poluchenija biciklicheskikh laktol-metil-ehfirov
HU178202B (en) * 1977-09-26 1982-03-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new,optically active and racemic bicyclic acetals and merkaptals
FR2550799B1 (fr) * 1983-08-17 1986-02-21 Commissariat Energie Atomique Compose marque par une enzyme, son procede de preparation et son utilisation en enzymoimmunologie
DE68929435T2 (de) * 1988-09-06 2003-07-17 Pharmacia Ab, Stockholm Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
US5359095A (en) 1990-08-08 1994-10-25 Pharmacia Ab Method for synthesis of prostaglandin derivatives
SE9002596D0 (sv) * 1990-08-08 1990-08-08 Pharmacia Ab A method for synthesis of prostaglandin derivatives
GB9025509D0 (en) * 1990-11-23 1991-01-09 Fujisawa Pharmaceutical Co New amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
HU212570B (en) * 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JPH10298446A (ja) * 1997-04-25 1998-11-10 Mitsui Chem Inc 黄色建染染料の製造方法
US7166730B2 (en) 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
DE10226942A1 (de) * 2002-06-17 2003-12-24 Symrise Gmbh & Co Kg Verwendung von Mandelsäurealkylamiden als Aromastoffe
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
GB0329379D0 (en) 2003-12-19 2004-01-21 Johnson Matthey Plc Prostaglandin synthesis
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
AR071312A1 (es) * 2008-04-09 2010-06-09 Scinopharm Taiwan Ltd Proceso para la preparacion de analogos de prostaglandina y sus intermediarios
EP2135860A1 (en) * 2008-06-20 2009-12-23 Sandoz AG Improved process for the production of bimatoprost
GB0819182D0 (en) * 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
WO2010096123A2 (en) * 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US9333158B2 (en) * 2009-03-16 2016-05-10 Nissan Chemical Industries, Ltd. Spray base material including low-molecular gelator
US8519178B2 (en) * 2009-06-22 2013-08-27 Johnson Matthey Public Limited Company Method for the purification of prostaglandins
GB0911000D0 (en) * 2009-06-25 2009-08-12 Givaudan Sa Compounds
US8901319B2 (en) * 2009-10-16 2014-12-02 Cayman Chemical Company, Incorporated Process for the preparation of F-series prostaglandins
KR20120081227A (ko) 2009-11-02 2012-07-18 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 비마토프로스트 결정 및 그의 제조방법과 용도
WO2011055377A1 (en) 2009-11-05 2011-05-12 Biocon Limited A novel process for the preparation of prostaglandins and intermediates thereof
KR20120085330A (ko) * 2009-11-23 2012-07-31 알러간, 인코포레이티드 결정형 ｉｉ의 ７?〔３,５?다이하이드록시?２?(３?하이드록시?５?페닐?펜트?１?에닐)?사이클로펜틸〕?ｎ?에틸?헵트?５?엔아마이드(비마토프로스트), 그의 제조방법 및 이용방법
EP2495235B1 (en) * 2011-03-04 2015-08-05 Newchem S.p.A. Process for the synthesis of prostaglandins and intermediates thereof
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1774417A (zh) * 2001-05-31 2006-05-17 梵泰克实验室有限公司 17－苯基－18,19,20－去三甲－前列腺素F2α及其衍生物的制备方法
CN1533372A (zh) * 2001-07-17 2004-09-29 �������Ŷ���Լ��������˾ 制备拉坦前列腺素的方法和中间体
US20090163596A1 (en) * 2006-08-29 2009-06-25 Arie Gutman Bimatoprost crystalline form I

Also Published As

Publication number Publication date
MX341839B (es) 2016-09-05
RU2013158952A (ru) 2015-07-20
RU2618223C2 (ru) 2017-05-03
WO2012164324A9 (en) 2014-01-09
TWI653222B (zh) 2019-03-11
JP6212485B2 (ja) 2017-10-11
TW201708190A (zh) 2017-03-01
US20160137602A1 (en) 2016-05-19
US9573892B2 (en) 2017-02-21
PL2723714T3 (pl) 2018-02-28
JP2017061555A (ja) 2017-03-30
KR102038048B1 (ko) 2019-10-30
IL229647A0 (en) 2014-01-30
TWI632131B (zh) 2018-08-11
CN106278982B (zh) 2019-06-14
BR112013030973A2 (pt) 2016-08-16
ZA201309357B (en) 2014-08-27
JP6693859B2 (ja) 2020-05-13
IL229647A (en) 2017-09-28
BR122021008918B1 (pt) 2021-08-10
US20160145207A1 (en) 2016-05-26
CA2837261A1 (en) 2012-12-06
TW201708191A (zh) 2017-03-01
KR102135550B1 (ko) 2020-07-21
CN106278982A (zh) 2017-01-04
EP2723714B1 (en) 2017-06-21
BR122021008946B1 (pt) 2021-08-10
TW201311629A (zh) 2013-03-16
BR112013030973A8 (pt) 2021-03-30
US9856213B2 (en) 2018-01-02
TWI653223B (zh) 2019-03-11
CN106316910A (zh) 2017-01-11
KR20200087871A (ko) 2020-07-21
KR102277188B1 (ko) 2021-07-15
MX2013014034A (es) 2015-06-17
JP2014527026A (ja) 2014-10-09
CN103649047A (zh) 2014-03-19
CA2837261C (en) 2020-12-15
CA3094762C (en) 2023-09-26
BR112013030973B1 (pt) 2021-08-10
CN103649047B (zh) 2017-01-11
JP6487410B2 (ja) 2019-03-20
CA3094762A1 (en) 2012-12-06
US20140135503A1 (en) 2014-05-15
JP2017075165A (ja) 2017-04-20
ES2636756T3 (es) 2017-10-09
PT2723714T (pt) 2017-08-18
EP2723714A1 (en) 2014-04-30
US9238621B2 (en) 2016-01-19
CA3209613A1 (en) 2012-12-06
KR20140053941A (ko) 2014-05-08
WO2012164324A1 (en) 2012-12-06
KR20190124804A (ko) 2019-11-05
HUE033642T2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
CN106278982B (zh) 用于制备前列腺素酰胺的新的方法
CN113214320A (zh) 一种瑞德西韦化合物的制备方法
KR20020046948A (ko) 에폭사이드 결정의 제조방법
CN112154140B (zh) 化合物及其在合成布瓦西坦(Brivaracetam)原料药中的用途
DK165005B (da) Analogifremgangsmaade til fremstilling af 4,5-dihydro-4-oxofuran-2-carboxylsyrederivater eller terapeutisk acceptable salte deraf
AU2003224108B9 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and method for the production thereof
CN116655612A (zh) 一种ezh2抑制剂的合成方法及应用
AU781974B2 (en) Anhydrous mirtazapine and process for preparing the same
CN110498762A (zh) 一种(2s,5r)-5-[(苄氧基)氨基]-哌啶-2-甲酸乙酯的合成方法
JP2002322166A (ja) エポキシド結晶の製造法
CN118530145A (zh) 一种达芦那韦关键中间体的合成方法
CN116496314A (zh) 一种(2s,4s)-1-(叔丁氧羰基)-4-(叔丁基二甲基硅氧基)-2-甲基吡咯烷-2-羧酸的制备方法
EP1313702A1 (en) Process for crystallizing enantiomerically enriched 2-acetylthio-3-phenylpropionic acid
JPH02221266A (ja) Ｎ，ｎ―ビス―［３―（３，４，５―トリメトキシベンゾイルオキシ）プロピル］ホモピペラジンの製造方法
CN109721524A (zh) 一种雷米普利的精制方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170125